

Research advances in antibody therapeutics, - Overview –

Masahiro Nishibori¹ and Shuji Mori²

(¹Okayama Univ, Grad Sch Med Dent Pharm Sci, ²Shujitsu Univ, Sch Pharm)

The technology to produce monoclonal antibody (mAb) was established in mid 1970th and mAb has been used widely as research tool in life sciences and for the diagnostic purpose in clinical medicine. The development of bioengineering for the production of chimera and humanized Abs now has opened new era in which mAbs are used as therapeutic drugs in the treatment of rheumatic arthritis and cancer. Thus, it is expected that Ab drugs will be much more important in clinical medicine in the near future. In this symposium, the revolution of Ab bioengineering and its potential application to the treatment of diseases will be discussed.